Naoko Takebe - Concepedia

Author

Naoko Takebe

National Cancer Institute ORCID

Also Known As

N TAKEBE, N Takebe, N. TAKEBE, N. Takebe, NAOKO TAKEBE, Naoko Takebe, Takebe, Naoko

651

Publications

12K

Citations

H-Index

101

Concepts

All Affiliations

National Cancer Institute National Institutes of Health The University of Texas MD Anderson Cancer Center Frederick National Laboratory for Cancer Research Memorial Sloan Kettering Cancer Center

About

Naoko Takebe is an author at National Cancer Institute specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	56	2.4K
2	Health Sciences	11	12	437
3	Natural Sciences	4	4	130
4	Public Health	2	2	158
5	Engineering	1	1	24

Naoko Takebe

105

Publications

6.5K

Citations

H-Index

Page 1

	Year	Citations
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer Daniel V.T. Catenacci, Melissa R. Junttila, Theodore Karrison, Journal of Clinical Oncology	2015	524
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032 Giles Robinson, Brent A. Orr, Gang Wu, Journal of Clinical Oncology	2015	448
Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma Edward Kim, Vaibhav Sahai, Ethan V. Abel, Clinical Cancer Research	2014	302
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) Keith T. Flaherty, Robert J. Gray, Alice P. Chen, Journal of Clinical Oncology	2020	281
Review: Targeting the Hedgehog pathway in cancer Sachin Gupta, Naoko Takebe, Patricia LoRusso Therapeutic Advances in Medical Oncology OncologyHedgehog PathwayMedicineHh SignalingPharmacology	2010	253
Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study Amar Gajjar, Clinton F. Stewart, David W. Ellison, Clinical Cancer Research	2013	211
US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL Farhad Ravandi, Megan Othus, Susan O’Brien, Blood Advances	2016	187
Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer Faye M. Johnson, B. Nebiyou Bekele, Lei Feng, Journal of Clinical Oncology	2010	165
Controversies in Cancer Stem Cells: Targeting Embryonic Signaling Pathways Naoko Takebe, S. Percy Ivy Clinical Cancer Research Lineage PlasticityInduced Pluripotent Stem CellDevelopmental BiologySignaling PathwayMedicine	2010	130
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab Sandra P. D’Angelo, Alexander N. Shoushtari, Mary Louise Keohan, Clinical Cancer Research	2016	125

Page 1